Biogen sues Teva over MS generic
PictureDesignSwiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biogen, biotech, injunction, US Court of Appeals for the Federal Circuit, Banner Life Sciences, Sangamo, collaboration, gene therapies